Modeling heart failure in animal models for novel drug discovery and development

被引:10
|
作者
Janssen, Paul M. L. [1 ,2 ,3 ]
Elnakish, Mohammad T. [1 ,2 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Dept Physiol & Cell Biol, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
Animal model; human heart failure; ischemia; hypertension; contraction; LEFT-VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION MODEL; CONTRACTILE DYSFUNCTION; ANGIOTENSIN-II; CARDIAC-FUNCTION; CANINE MODEL; IN-VIVO; FORCE; MOUSE; RAT;
D O I
10.1080/17460441.2019.1582636
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: When investigating drugs that treat heart diseases, it is critical when choosing an animal model for the said model to produce data that is translatable to the human patient population, while keeping in mind the principles of reduction, refinement, and replacement of the animal model in the research. Areas covered: In this review, the authors focus on mammalian models developed to study the impact of drug treatments on human heart failure. Furthermore, the authors address human patient variability and animal model invariability as well as the considerations that need to be made regarding choice of species. Finally, the authors discuss some of the most common models for the two most prominent human heart failure etiologies; increased load on the heart and myocardial ischemia. Expert opinion: In the authors' opinion, the data generated by drug studies is often heavily impacted by the choice of species and the physiologically relevant conditions under which the data are collected. Approaches that use multiple models and are not restricted to small rodents but involve some verification on larger mammals or on human myocardium, are needed to advance drug discovery for the very large patient population that suffers from heart failure.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 50 条
  • [41] Drug discovery and development for acute heart failure drugs: Are expectations too high?
    Pollesello, Piero
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 172 (01) : 11 - 13
  • [42] In vitro models of neuromuscular junctions and their potential for novel drug discovery and development
    Vila, Olaia F.
    Qu, Yihuai
    Vunjak-Novakovic, Gordana
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (03) : 307 - 317
  • [43] Genetic and Tissue Engineering Approaches to Modeling the Mechanics of Human Heart Failure for Drug Discovery
    Greenberg, Michael J.
    Daily, Neil J.
    Wang, Ann
    Conway, Michael K.
    Wakatsuki, Tetsuro
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2018, 5
  • [44] Animal models for Niemann-Pick type C: implications for drug discovery & development
    Fog, Cathrine K.
    Kirkegaar, Thomas
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (05) : 499 - 509
  • [45] Progress in the development of animal models of acute kidney injury and its impact on drug discovery
    Sanz, Ana B.
    Dolores Sanchez-Nino, Maria
    Martin-Cleary, Catalina
    Ortiz, Alberto
    Ramos, Adrian M.
    EXPERT OPINION ON DRUG DISCOVERY, 2013, 8 (07) : 879 - 895
  • [46] The development of swine models in drug discovery and development
    Swindle, M. Michael
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (14) : 1771 - 1772
  • [47] in Heart Failure Drug Development
    Hussain, Aliza
    Misra, Arunima
    Bozkurt, Biykem
    CARDIAC FAILURE REVIEW, 2022, 8
  • [48] The identification of contributory mechanisms for the development and progression of congestive heart failure in animal models
    Iannini, JP
    Spinale, FG
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1996, 15 (11): : 1138 - 1150
  • [49] Pitfalls for cancer drug discovery with "genetic" animal models
    Sausville, E.
    EJC SUPPLEMENTS, 2008, 6 (12): : 7 - 7
  • [50] Cell and small animal models for phenotypic drug discovery
    Szabo, Mihaly
    Akusjarvi, Sara Svensson
    Saxena, Ankur
    Liu, Jianping
    Chandrasekar, Gayathri
    Kitambi, Satish S.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1957 - 1967